Comparison |
| Alternate Manufacturer Number |
| | | 3406527 | 3406535 |
| Container Type |
Prefilled Syringe | Prefilled Syringe | Single-Dose Vial | Prefilled Syringe | Prefilled Syringe |
| Generic Drug Code |
| 35944 | 28272 | 37413 | 37413 |
| Generic Drug Name |
Meningococcal Groups A, B, C, W, and Y Vaccine | Meningococcal Group B Vaccine | Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Preservative Free | Meningococcal Group B Vaccine | Meningococcal Group B Vaccine |
| NDC Number |
00069060005 | 58160097620 | 58160095509 | 00005010005 | 00005010010 |
| Product Dating |
McKesson Acceptable Dating: we will ship >= 180 days | McKesson Acceptable Dating: we will ship >= 90 days | McKesson Acceptable Dating: we will ship >= 90 days | McKesson Acceptable Dating: we will ship >= 180 days | McKesson Acceptable Dating: we will ship >= 180 days |
| Strength |
| 50 mcg - 50 mcg / 0.5 mL | 10 mcg - 5 mcg / 0.5 mL | 120 mcg / 0.5 mL | 120 mcg / 0.5 mL |
| UNSPSC Code |
51201634 | 51201610 | 51201610 | 51201610 | 51201610 |
| User |
Indicated for People 10 to 25 Years of Age | Indicated for People 10 to 25 Years of Age | Indicated for People 2 Months to 55 Years of Age | Indicated for People 10 to 25 Years of Age | Indicated for People 10 to 25 Years of Age |
| Application |
Meningitis Vaccine | Meningitis Vaccine | Meningitis Vaccine | Meningitis Vaccine | Meningitis Vaccine |
| Country of Origin |
Unknown | Unknown | Unknown | Unknown | Unknown |
| Dosage Form |
Injection | Injection | Injection | Injection | Injection |
| Storage Requirements |
Requires Refrigeration | Requires Refrigeration | Requires Refrigeration | Requires Refrigeration | Requires Refrigeration |
| Type |
Intramuscular | Intramuscular | Intramuscular | Intramuscular | Intramuscular |
| Volume |
0.5 mL | 0.5 mL | 0.5 mL | 0.5 mL | 0.5 mL |
| Features and Benefits |
- PENBRAYA™ (Meningococcal Groups A, B, C, W, and Y Vaccine), suspension for intramuscular injection
- PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y
|
- BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B
- BEXSERO is approved for use in individuals 10 through 25 years of age
- BEXSERO is supplied as a 0.5 mL suspension in a glass pre-filled syringe
- 10 Syringes
|
- MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons 2 months through 55 years of age
- MENVEO is supplied in two vials that must be combined prior to administration: reconstitute the MenA lyophilized conjugate vaccine component with the MenCYW-135 liquid conjugate vaccine component immediately before administration
|
- Trumenba is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B
- Trumenba is a suspension for intramuscular injection in 0.5 mL single-dose prefilled syringe
- 5 Syringes
|
- Trumenba is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B
- Trumenba is a suspension for intramuscular injection in 0.5 mL single-dose prefilled syringe
- 10 Syringes
|
